Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
276.4 SEK | +1.10% |
|
+2.37% | +3.52% |
06-19 | Sobi Wins EU Approval for Hemophilia A Drug Altuvoct | MT |
06-19 | European Commission Grants Sobi® Marketing Authorisation for Altuvoct? for Treatment of Haemophilia A | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.52% | 8.91B | |
+2.22% | 93.91B | |
-1.32% | 38.4B | |
-13.44% | 32.61B | |
+76.30% | 28.2B | |
-13.11% | 15.91B | |
+0.68% | 14.22B | |
-12.06% | 11.54B | |
+185.28% | 10.74B | |
-53.00% | 9.47B |
- Stock Market
- Equities
- SOBI Stock
- News Swedish Orphan Biovitrum AB
- Swedish Orphan Biovitrum : Sobi, Apellis Blood Disease Drug Shown Better Than Standard of Care in Study